Evaluating Patients for Narcolepsy
There are 2 separate sets of diagnostic criteria that can be used to evaluate patients for narcolepsy.1,2
Diagnostic Criteria:
Screening tools may help with symptom assessment3,4
View the tools
ICSD-3 diagnostic criteria1
The American Academy of Sleep medicine (AASM) International Classification of Sleep Disorders - Third Edition (ICSD-3) contains diagnostic criteria for sleep disorders, including narcolepsy.
Narcolepsy type 1
- Excessive daytime sleepiness daily for ≥3 months*
- One or both of the following:
- Cataplexy and mean sleep latency ≤8 minutes and ≥2 SOREMPs on MSLT; SOREMP (≤15 min after sleep onset) on preceding nocturnal PSG may replace one of the SOREMPs on MSLT†
- Low or absent CSF hypocretin-1 levels‡
Narcolepsy type 2
- Excessive daytime sleepiness and MSLT findings as above, but without cataplexy§
- CSF hypocretin-1 levels are unknown or are above the threshold for narcolepsy type 1§
- The hypersomnolence and/or MSLT findings are not better explained by other causes, such as insufficient sleep, OSA, delayed sleep phase disorder, or the effect of medications or substances or their withdrawal
Notes:
*In young children, narcolepsy may sometimes present as excessively long night sleep or as resumption of previously discontinued daytime napping.
†If narcolepsy type 1 is strongly suspected clinically, but MSLT criteria are not met, consider repeating the MSLT.
‡Low or absent CSF hypocretin-1 levels = CSF hypocretin-1 concentration measured by immunoreactivity is either ≤110 pg/mL or <1/3 of mean values in healthy subjects using the same assay.
§If cataplexy develops later or low or absent CSF hypocretin-1 levels are discovered, reclassify as narcolepsy type 1.
CSF, cerebrospinal fluid; ICSD, International Classification of Sleep Disorders; MSLT, multiple sleep latency test; PSG, polysomnography; SOREMP, sleep-onset REM period.
DSM-5 diagnostic criteria2
The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) contains diagnostic criteria for sleep-wake disorders, including narcolepsy, designed for use by mental health and medical clinicians.
- Recurrent periods of an irrepressible need to sleep, lapsing into sleep, or napping occurring within the same day. These must have been occurring ≥3 times per week over the past 3 months
- The presence of at least one of the following:
- Episodes of cataplexy, defined as either (a) or (b), occurring at least a few times per month:
- In individuals with long-standing disease, brief (seconds to minutes) episodes of sudden bilateral loss of muscle tone with maintained consciousness that are precipitated by laughter or joking
- In children or in individuals within 6 months of onset, spontaneous grimaces or jaw-opening episodes with tongue thrusting or a global hypotonia, without any obvious emotional triggers
- Hypocretin deficiency, as measured using CSF hypocretin-1 immunoreactivity values (≤1/3 of values obtained in healthy subjects tested using the same assay, or ≤110 pg/mL). Low CSF levels of hypocretin-1 must not be observed in the context of acute brain injury, inflammation, or infection
- Nocturnal sleep PSG showing REM sleep latency ≤15 minutes, or an MSLT showing a mean sleep latency ≤8 minutes and ≥2 SOREMPs
Notes:
DSM, Diagnostic and Statistical Manual of Mental Disorders.
- American Academy of Sleep Medicine. Central disorders of hypersomnolence. In: The International Classification of Sleep Disorders – Third Edition (ICSD-3) Online Version. Darien, IL: American Academy of Sleep Medicine; 2014.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
- Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
- Bassetti CL. Spectrum of narcolepsy. In: Baumann CR, Bassetti CL, Scammell TE, eds. Narcolepsy: Pathophysiology, Diagnosis, and Treatment. New York, NY: Springer Science+Business Media; 2011:309-319.